New Rat Study: BPC-157 Counteracts Gentamicin-Induced Kidney Injury

BPC-157’s research literature has been, until now, concentrated in three areas: gastrointestinal tissue, tendon-to-bone healing, and vascular/angiogenesis models — all discussed on this site’s BPC-157 product page. A new study published in the Journal of Physiology and Pharmacology (2026) extends that base into a different organ system entirely: the kidney. Authored by the University of Zagreb group that first characterized BPC-157 in the 1990s, it asks whether the peptide can counteract nephrotoxicity induced by gentamicin, an antibiotic well known in both clinical and research settings for damaging kidney tissue at high doses.

What the researchers did

The team induced severe kidney injury in rats using daily intraperitoneal gentamicin (100 mg/kg) over eight days — a well-established nephrotoxicity model. Against that injury, they tested BPC-157 at two doses, delivered either in drinking water or by daily intraperitoneal injection.

The distinctive part of the design is what the authors call a “triple nitric oxide-agent approach.” Because BPC-157’s proposed mechanism centers on modulating the nitric oxide (NO) system, the researchers layered in three additional conditions to probe that system directly: L-NAME, which inhibits NO synthesis; L-arginine, which is a substrate that overstimulates NO production; and the two combined, which effectively locks the NO system in place. Running BPC-157 treatment against all three conditions was intended to show whether its protective effect held up regardless of which direction the NO system was being pushed.

What they found

Rats treated with BPC-157 showed near-normal clinical presentation despite the gentamicin insult: serum urea and creatinine stayed close to normal ranges, diuresis was maintained (both polyuria and oliguria were avoided), kidney mass did not increase, and microscopy showed largely preserved tubular epithelium and nephron structure. At the tissue level, BPC-157 counteracted the gentamicin-driven rise in malondialdehyde (a marker of oxidative stress) and reversed the gentamicin-driven drop in both NO and superoxide dismutase, an antioxidant enzyme.

The NO-agent arms told a more granular story. L-arginine (which overstimulates NO production) worsened the injury — higher urea and creatinine, more pronounced polyuria and oliguria. L-NAME (which blocks NO production) had the opposite, injury-limiting effect on its own. Combining the two produced the worst outcomes of any group, effectively canceling out L-NAME’s protective tendency. Against all of these conditions, BPC-157 treatment — whether given orally or intraperitoneally — overrode the pattern and preserved kidney function and structure.

Why this is a useful addition to the research picture

The core interest here isn’t just that BPC-157 showed a protective effect in another organ injury model — it’s the mechanistic framing. By testing BPC-157 against a full spread of NO-system states (blocked, overstimulated, and locked), the authors argue the peptide’s effect isn’t contingent on any single point in that pathway, which is consistent with the NO-system modulation mechanism already described in BPC-157’s existing research literature on angiogenesis and tissue repair. For a reader tracking BPC-157’s mechanism specifically, this paper is a data point in a related but previously undocumented context: drug-induced nephrotoxicity rather than gastric, tendon, or vascular injury.

What it doesn’t show

This is a rodent study, not a human trial, and it says nothing about safety or effect in humans. It also comes from a single, long-running research group — the same Zagreb lab responsible for much of BPC-157’s foundational literature — so independent replication by other groups would strengthen confidence in the findings. The “triple NO-agent” design is informative for probing mechanism, but the pharmacological manipulation of the NO system in this model doesn’t map neatly onto normal physiology, and the study doesn’t identify a specific molecular target within the NO pathway. It’s one preclinical data point in a specific drug-induced injury model, not evidence of a general kidney-protective effect.

Further reading

Vukoja I, Vlainic J, Francina M, et al. “Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation: evidence from a triple nitric oxide-agent approach in rats.” Journal of Physiology and Pharmacology, 77(3), 377-395 (2026). pubmed.ncbi.nlm.nih.gov/42533460 · doi.org/10.26402/jpp.2026.3.08